Výsledky vyhledávání - "Kaan Kavakli"

Akademický článek

Challenges associated with access to recently developed hemophilia treatments in routine care: perspectives of healthcare professionals

Autor: Karin Berger, Roxy H. O’Rourke, Matteo Nicola Dario Di Minno, Angelika Batorova, Kaan Kavakli, Pier Mannuccio Mannucci, Wolfgang Schramm, Rhonda L. Bohn, Louis Aledort

Publikováno v: Haematologica, Vol 999, Iss 1 (2024)

The treatment landscape for haemophilia continues to rapidly develop, and expectations for future treatment success are high. There is limited information on the challenges to accessing new and innovative therapies. The aim of this study was to explo

Externí odkaz: https://doaj.org/article/af4046fe78af487687f795c7a684cdf0

Zobrazit plný text záznamu

Akademický článek

S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS

Autor: Gili Kenet, Beatrice Nolan, Bulent Zulfikar, Bulent Antmen, Peter Kampmann, Tadashi Matsushita, Chur-Woo You, Kateryna Vilchevska, Catherine N. Bag, Azizan Sharif, Flora Peyvandi, Guy Young, Claude Negrier, Christian Sussebach, Fadi Shammas, Shauna Andersson, Baisong Mei, Kaan Kavakli

Publikováno v: HemaSphere, Vol 7, p e643526e (2023)

Externí odkaz: https://doaj.org/article/2a45dff57f9c4ff2bedf75d75d9983b0

Zobrazit plný text záznamu

Akademický článek

S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX

Autor: Gili Kenet, Beatrice Nolan, Bulent Zulfikar, Bulent Antmen, Guy Young, Jiarui Chi, Marion Afonso, Viridiana Cano, Christian Sussebach, Shauna Andersson, Kaan Kavakli

Publikováno v: HemaSphere, Vol 7, p e4531731 (2023)

Externí odkaz: https://doaj.org/article/3dbcd2c1ffa24c5e98bfa7cf7643e274

Zobrazit plný text záznamu

Akademický článek

Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study

Autor: Steven R. Lentz, Kaan Kavakli, Robert Klamroth, Mudi Misgav, Azusa Nagao, Alberto Tosetto, Pernille Juul Jørgensen, Marek Zak, Laszlo Nemes

Publikováno v: Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 2, Pp n/a-n/a (2022)

Abstract Background N8‐GP (turoctocog alfa pegol; Esperoct) is a glycoPEGylated human recombinant factor VIII (FVIII). Objectives Pathfinder8 (NCT01480180) was a phase 3, multinational, open‐label, nonrandomized trial to investigate the long‐te

Externí odkaz: https://doaj.org/article/f97499a8365a4b5fbf4ba7b99c85a0bc

Zobrazit plný text záznamu

Akademický článek

Plasma‐derived factor X concentrate compassionate use for hereditary factor X deficiency: Long‐term safety and efficacy in a retrospective data‐collection study

Autor: James N. Huang, Ri Liesner, Steven K. Austin, Kaan Kavakli, Chioma Akanezi

Publikováno v: Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 5, Pp n/a-n/a (2021)

Abstract Background Coagadex is a high‐purity plasma‐derived factor X concentrate (pdFX) developed to treat hereditary factor X deficiency (FXD). Objective Evaluate the efficacy and safety of pdFX administered to patients with hereditary FXD. Met

Externí odkaz: https://doaj.org/article/4e9290cfd4a24635a61529d807f095f6

Zobrazit plný text záznamu

Akademický článek

The Effect of Self-infusion and Patient Education on Treatment Compliance in Hemophilia Patients

Autor: Elif Güler kazancı, Mehmet Can Uğur, Yeşim Oymak, Kaan Kavakli

Publikováno v: Journal of Behçet Uz Children's Hospital, Vol 9, Iss 2, Pp 160-163 (2019)

INTRODUCTION: Compliance to treatment regimens is a current issue in the treatment of hemophilia. These problems are widely reported. We aimed to investigate the effect of self-infusion and patient education on treatment compliance in hemophilia pati

Externí odkaz: https://doaj.org/article/220c6f57b7ba4353988ea8100bba2b64

Zobrazit plný text záznamu

Akademický článek

Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses

Autor: Francesco Demartis, Angelika Batorova, Hervé Chambost, Peyman Eshghi, Mehran Karimi, Kaan Kavakli, Soraya Benchikh El Fegoun, Katarina Cepo, Lene Sommer Vestergaard, Gary Benson

Publikováno v: TH Open, Vol 01, Iss 02, Pp e130-e138 (2017)

Treating hemophilia A or B patients with inhibitors is particularly challenging, as they do not respond to replacement therapy with factor VIII or factor IX concentrates. A room temperature–stable formulation of recombinant activated factor VII (rF

Externí odkaz: https://doaj.org/article/b9bc286a1f164591a2f58cb953d3c22d

Zobrazit plný text záznamu

Akademický článek

Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough

Autor: Yilmaz Ay, Deniz Yilmaz, Can Balkan, Bulent Karapinar, Nihal Karadas, Kaan Kavakli

Publikováno v: Case Reports in Oncology, Vol 4, Iss 2, Pp 323-326 (2011)

BCR-ABL fusion gene t(9;22)(q34;q11) occurs in only 3% of pediatric acute lymphoblastic leukemia (ALL) cases. Previously, less than 40% of Philadelphia-positive ALL patients were cured with intensive chemotherapy. The use of imatinib (340 mg/m2/day)

Externí odkaz: https://doaj.org/article/c20932e788df410f9e32073e3593b657

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání